EAP is delighted to announce the launch of the ‘One Less Thing’ campaign with UNICEF, promoting routine vaccination for children in Europe.
Routine vaccination rates have decreased in recent years in light of the Covid-19 pandemic and the Covid vaccine roll out. This means there is an increasing need and opportunity to refocus on life-saving childhood vaccines, in order to ensure that no child is left behind. The European Academy of Paediatrics (EAP) has partnered with UNICEF ECARO to create a social media campaign to strengthen confidence in childhood vaccines and demand for routine immunization. The aim is to encourage caregivers in Europe and the Central Asian region to get young children vaccinated.
You can follow the campaign on our social media channels: Twitter, Facebook and LinkedIn.
For more information about routine vaccination, please contact your paediatrician or read more on EAP’s website.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.
